Claims for harm linked to Dupixent in Mississippi

Mississippi has historically been one of the most plaintiff-friendly states in pharmaceutical litigation, though tort reform legislation in the early 2000s modified venue selection and other procedural rules. An estimated 22,000 Mississippi residents have been prescribed Dupixent since 2017, with prescribing concentrated through the University of Mississippi Medical Center in Jackson, the state's only academic medical center and NCI Community Oncology Research Program site. Mississippi's pure comparative fault system — allowing recovery regardless of plaintiff fault percentage — is plaintiff-favorable. The state's 3-year SOL provides adequate time, and Mississippi's jury pools, particularly in the Southern District and state courts in the Jackson and Delta regions, have shown willingness to hold pharmaceutical companies accountable.

For the overall process and updates, read the Claims for harm linked to Dupixent overview. This page covers the local information available for Mississippi.